Corporate report
Annex B: Awards to PHE research funding 2019 to 2020
Updated 25 May 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/phe-research-annual-review/annex-b-awards-to-phe-research-funding-2019-to-2020
Awards to Public Health England (PHE) in 2019 to 2020
| Title | Directorate | Income to PHE | Funding source | Lead organisation | Collaborators |
|---|---|---|---|---|---|
| Therapeutic Development | NIS | £6,083,046 | Biomedical Advanced Research and Development Authority (BARDA) | Commercial | PHE |
| Natural history of Filovirus | NIS | £1,493,635 | Biomedical Advanced Research and Development Authority | INSERM | PHE |
| Baseline shale gas radon monitoring | HPMD | £98,000 | Dept for Business, Energy and Industrial Strategy (BEIS) | British Geological Survey | PHE |
| Evaluation of sugar transport mutants of Mycobacterium tuberculosis in a model of TB disease | NIS | £41,843 | Wellcome Trust | University of Warwick | PHE |
| Measles IgM Point of Care Trial: Cameroon /Uganda study | NIS | £51,845 | WHO | PHE | |
| Susceptibility and resistance of uropathogens causing lower urinary tract infections | NIS | £32,068 | Commercial | Commercial | PHE |
| EQA scheme for laboratory characterisation of Bordetella pertussis | NIS | £34,536 | European Centre for Disease Prevention and Control | University of Turku | PHE |
| Immunological Responses to emerging pheblo- and arenaviruses | NIS | £29,433 | Medical Research Council | University of Oxford | PHE |
| Human T-lymphotropic virus seroprevalence in HIV pre-exposure prophylaxis users | NIS | £18,200 | Commercial | PHE | Imperial College London |
| Epigenetic Ageing | HPMD | £197,016 | Charity | PHE | |
| Development of a Low-Cost Fluoropolymer Microfluidic Platform for the Detection of CCHFV Antibodies | NIS | £49,147 | Medical Research Council | PHE | Liverpool School of Tropical Medicine, University of Reading, commercial entity |
| Inactivation of acutely infected cellular samples for downstream immunological processing | NIS | £42,542 | Medical Research Council | PHE | Liverpool School of Tropical Medicine |
| Development of Lassa Fever vaccine | NIS | £53,738 | Medical Research Council | PHE | Liverpool School of Tropical Medicine |
| Modelling the likelihood and feasibility of measles and rubella elimination in 98 countries | NIS | £22,446 | World Health Organization | PHE | Imperial College London |
| Building an Evidence-based Intervention for Emergency Services Personnel | HPMD | £60,000 | College of Policing | PHE | College of Policing |
| Stability of a novel vaccine formulation | NIS | £34,227 | Commercial | Commercial | PHE |
| Estimating hepatitis C burden in EU/EEA | NIS | £56,109 | European Centre for Disease prevention and Control (ECDC) | PHE | MRC Biostatistics Unit |
| A comprehensive model and economic evaluation of HCV elimination amongst people who inject drugs | NIS | £31,184 | National Institute for Health Research | University of Bristol | PHE and 6 other collaborating partners |
| The European Virus Archive Global (EVA-GLOBAL) | NIS | £227,944 | European Commission | Universite D’Aix-Marseille | PHE and 37 other project partners |
| ERA-4-TB | NIS | £1,302,185 | European Commission | Universidad Carlos III de Madrid | PHE |
| Development of a more Effective Vaccine against Tuberculosis | NIS | £883,644 | Charity | University of Oxford | PHE |
| Clinical assay development and testing for Anthrax vaccine | NIS | £675,039 | Commercial | PHE | |
| EROS study: Enabling diabetic RetinOpathy Screening | HI | £15,933 | National Institute for Health Research | City University of London | PHE |
| POSTBOX- Patient Outcomes from Second film readers and Test threshold relaxation in Breast Screening | HI | £28,419 | National Institute for Health Research | University of Warwick | PHE |
| Assessment of strain coverage of the 4CMenB vaccine among invasive meningococcal strains in England and Wales | NIS | £72,294 | Commercial | Commercial | PHE |
| Pneumococcal carriage study in adults with pneumonia | NIS | £86,666 | Commercial | University of Nottingham | PHE |
| Whole genome sequencing of S. pneumoniae isolates | NIS | £15,040 | German National Reference Center for Streptococci | German National Reference Center for Streptococci | PHE |
| TB vaccine evaluation - immunogenicity | NIS | £309,547 | US National Institutes of Health | Commercial | PHE |
| Support for Applied Research Collaboration (ARC) East of England | HI | £59,084 | National Institute for Health Research | University of Cambridge | PHE |
| Integrating genomic surveillance and ecological modelling to maximise pneumococcal vaccine efficacy | NIS | £147,540 | Medical Research Council | Imperial College London | PHE and The London School of Hygiene and Tropical Medicine |
| Levels and trends of Antimicrobial Resistance in Campylobacter spp. from chicken reared in the UK | NIS | £67,512 | Food Standards Agency | PHE | |
| Bayesian predictive model to guide empiric antibiotic switches. | NIS | £119,804 | Medical Research Council | University of Bristol | PHE |
| The discovery and characterisation of antimicrobials that enhance pyrazinamide activity against Mycobacterium tuberculosis | NIS | £84,138 | Charity | PHE | Commercial |
| Irradiation testing of biological models | NIS | £9,938 | European Space Agency | Open University | PHE |
| Development of an improved Crimean Congo Haemorrhagic Fever Virus (CCHFV) diagnostic assay for biosurveillance in Turkey | NIS | £144,727 | Newton Fund | Cumhuriyet University, Turkey | PHE |
| The Evaluation of Azetidines against Mycobacterium tuberculosis | NIS | £62,882 | Engineering and Physical Sciences Research Council | University of Birmingham | PHE |
| Joint action to strengthen preparedness in the EU against serious cross-border threats to health and international health regulations | HPMD | £368,527 | European Commission | National Institute for Health and Welfare, Finland | PHE |
| Ecological and Epidemiological Investigation of Crimean-Congo hemorrhagic fever virus (CCHFV) in Azerbaijan | NIS | £482,728 | US Defense Threat Reduction Agency | Azerbaijan Ministry of Health | PHE |
| Evaluation of planning policies to regulate takeaway food outlets to improve health in England | HI | £35,484 | National Institute for Health Research | University of Cambridge | PHE |
| In vitro activity of cephlosporin against Pseudomonas aeruginosa | NIS | £16,202 | Commercial | Commercial | PHE |
| NanoHarmony | HPMD | £163,297 | European Commission | German Federal Institute for Occupational Safety and Health | PHE and several other project partners |
| Bacterial impedance cytometry | NIS | £432,220 | National Institute for Health Research | PHE | University of Southampton |
| Evaluation of maternal vaccination against Pertussis | NIS | £220,000 | Department of Health & Social Care | University of Oxford | PHE |
| Pipeline for development of peptide based antibacterial agents | NIS | £304,589 | Medical Research Council | King’s College London | PHE, University of Sheffield |
| Improving children’s digital mental wellbeing: Assessing the Own-It app | HI | £13,251 | eNurture Network | BBC | PHE |
| High containment studies to support product development | NIS | £1,038,082 | Coalition for Epidemic Preparedness Innovations | PHE | |
| Ebola virus disease: Correlates of Protection | NIS | £193,937 | U.S. Food and Drug Administration | PHE | |
| European network for research, prevention and control of the 2019-nCoV Pandemic | NIS | £105,229 | European Commission | Commercial | PHE and multiple project partners |
| EDCPT PREPARE | NIS | £195,092 | European And Developing Countries Clinical Trials Partnership (EDCPT) | St George’s University of London | PHE |
| Therapeutics for SARS-CoV2 | NIS | £254,619 | Commercial | Commercial | PHE |
| STAMINA | HPMD | £198,201 | European Commission | Commercial | PHE and several other project partners |
| Asthma UK Strategic Behavioural Analysis and Segmentation | HI | £33,379 | Asthma UK | PHE | |
| Nuclear Weapons Test Participant Study | HPMD | £330,269 | Ministry of Defence | PHE | |
| Germ Defense | HI | £18,432 | Medical Research Council | University of Southampton | PHE |
| A statistical framework for the apportionment of mixture of contaminants and their health effect determination | HPMD | £12,987 | Medical Research Council | Imperial College London | PHE, Kings College London |
| Evaluating and improving the efficacy of decontamination methods for toxic powders and corrosives | HPMD | £588,598 | NIHR | PHE | |
| The health and equity impacts of climate change mitigation measures on indoor and outdoor air pollution exposure - HEICCA | HPMD | £7,789 | Natural Environmental Research | University of Edinburgh | PHE and several other project partners |
| Networks to build interdisciplinary communities to address air quality challenges at the indoor/outdoor interface | HPMD | £14,293 | Natural Environment Research Council | Cranfield University | PHE and several other project partners |
| Optimising air quality and health benefits associated with a low-emission transport and mobility revolution in the UK (TRANSITION) | HPMD | £21,960 | Natural Environment Research Council | Sheffield University | PHE and several other project partners |
| Accelerator for identification of natural-product derived antimicrobials | NIS | £36,914 | Medical Research Council | University of Plymouth | PHE, University of Leeds, Bristol University, St Andrews University, Aberdeen University |
| Community-based interventions to improve the oral health of adults with severe and multiple disadvantages | C&R | £6,981 | National Institute for Health Research (NIHR) | Newcastle University | PHE |
| MANIFESTS | HPMD | £61,427 | European Commission | CEDRE | PHE and several other project partners |
| Peripheral arterial disease, Hypertension and Aneurysm Screening Trial (PHAST) | HI | £38,499 | National Institute for Health Research | University of Leicester | PHE |
| Vaccine efficacy study | NIS | £122,978 | Bill and Melinda Gates Foundation | Pirbright Institute | PHE |
Abbreviations
- C&R: Centres and Regions
- HI: Health Improvement
- HPMD: Health Protection and Medical Directorate
- NIS: National Infection Service